Tuesday, 29 June 2021

BioLargo’s Engineering Subsidiary on a Hot Streak with New Contract Awards







Westminster, CA – June 29, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced that its engineering subsidiary has recently been notified of several new contract awards. These recent wins are expected to increase the company’s operating cash flow, which will support its plans for top-line revenue growth and its efforts to commercialize a number of BioLargo’s patented environmental technologies.

These new contract wins are for work with 1) a resin manufacturing facility, 2) a dairy farm, 3) a new project at Picatinny Arsenal, one of the company’s long-time customers, 4) a potato processing plant, and 5) a US Air Force base, adding to the other seven bases already served by the company. Together, the new contracts are worth more than $1.2 million in revenue, most of which will be earned over the next six months. 

Dennis P. Calvert, President and CEO of BioLargo commented, “We believe these recent contract wins are evidence that our engineering subsidiary is on a trajectory toward aggressive growth, both in revenues and capacity. More cash flow means they can bring on new talent and expand their reach and credibility in the market as a reliable solutions provider for pressing environmental challenges, and empowers them to commercialize our patented innovations, including our water treatment technologies.” 

BioLargo Engineering, Sciences and Technologies, LLC (BLEST), was created to support three critical business initiatives:

  1. Scaling up and commercializing BioLargo’s innovative environmental technologies like its Advanced Oxidation System (AOS) energy-efficient water treatment technology, currently preparing for commercial trials.
  2. Building a customer-focused business that delivers trusted expert advice and practical engineering solutions to tackle some of the toughest environmental challenges.
  3. Continuing the company’s rich history of innovation. BLEST has already developed a potentially market-disruptive water treatment technology for per- and polyfluoroalkyl substances, or PFAS (read more at our blog: https://bit.ly/3jmIyWN), as well as an industrial waste mineral extraction technology. Both of these opportunities are in the final stages of preparing for commercial launch.

Mr. Calvert finished by saying, “These contract wins are a testament to our engineers’ technical skill and reputation as trusted project integrators. These two aspects are what will drive our patented, high-value innovations into the market.”

  

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863 

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday, 21 June 2021

Peer-Reviewed Scientific Paper Confirms Safety of Water Treated by BioLargo’s Advanced Oxidation System

Study demonstrates AOS generates less disinfection by-products than common wastewater treatment technologies 

Westminster, CA – June 21, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced the publication of a peer-reviewed scientific paper about its patented energy-efficient water disinfection technology the Advanced Oxidation System (AOS). The paper, which focused on quantifying the disinfection by-products generated by the AOS, represents a critical milestone in the commercialization of BioLargo’s innovative water treatment technology.

BioLargo’s ground-breaking AOS technology is a water treatment platform that provides high-level disinfection and consumes less electricity than competing technologies such as UV and ozone-based systems.  Significantly, the AOS removes pharmaceutical micropollutants from water to provide added value across diverse water treatment applications, including municipal wastewater treatment.

The study, led by the laboratory of Dr. Susana Kimura-Hara at the University of Calgary, assessed the disinfection by-products (DBPs) generated by the BioLargo AOS. The paper concluded that the levels of DBPs generated by the AOS were comparable to those found in ordinary tap water.

The paper’s abstract and summary can be accessed here: https://www.sciencedirect.com/science/article/abs/pii/S0043135421005388

As all water treatment technologies generate DBPs, the quantity and relative safety of disinfection byproducts generated by a given water treatment technology is an important consideration for customers deciding which technology to select for their needs. The results of this study therefore represent an important milestone for the AOS, which has a municipal wastewater treatment demonstration pilot underway near Montréal, Québec and is currently being readied for commercial trials.

This study corroborates the results of another peer-reviewed paper published earlier this year that showed the AOS does not increase the toxicity of treated water. Notably, that study also showed the AOS to be capable of negating the negative effects of two hard-to-treat micropollutants, with the paper’s author Dr. Greg Goss calling the AOS, “a major technical breakthrough for the treatment of micropollutants.


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Monday, 7 June 2021

BioLargo 2021 Annual Meeting of Stockholders Tuesday, June 15, 2021, 10:00 AM Pacific Time

Westminster, CA – June 7, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable clean- technologies and full-service environmental engineering company, will host its annual stockholder meeting on Tuesday June 15, 2021, at 10:00 am Pacific Time, via live webcast. In light of the continuing public health impact of the ongoing COVID-19 pandemic and to support the health and safety of the Company’s stockholders and attendees, the 2021 Annual Meeting will be held in a virtual-only meeting format.

Stockholders may register to attend the online Annual Meeting at this link:

https://agm.issuerdirect.com/blgo

Members of the Board and Management team will discuss the Company’s most recent annual and quarterly results and other general company matters, followed by a question-and-answer session with stockholders and management.

It is important that your shares be represented and voted at the Annual Meeting, whether or not you     plan to attend online. Stockholders of record as of April 19, 2021, may vote at the Annual Meeting. Please review the proxy statement and vote in accordance with the instructions you received.  

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

 

Friday, 4 June 2021

BioLargo (BLGO) to Present at LD Micro Invitational XI

Presentation on Wednesday, June 9 at 5:00 PM ET

Westminster, CA – June 4, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced today that it will be giving an investor presentation at the upcoming LD Micro virtual event on Wednesday, June 9, 2021, at 5:00 PM ET. BioLargo President and CEO Dennis P. Calvert will be giving the presentation.

Mr. Calvert will be discussing the company’s soon-to-launch sustainable water treatment technologies including its innovative solution for treating water contaminated with per- and polyfluoroalkyl substances (PFAS). Used in fire retardants and industrial facilities, PFAS contaminate municipal drinking water supplies across the country and the world, and represent a serious threat to human health.

“We got ahead of the curve by developing and commercializing an affordable and environmentally conscious technology that removes these toxic chemicals,” said Mr. Calvert. “The BioLargo AEC represents the most practical solution for this serious global problem. Watch our presentation to learn more about it and about our other emerging cleantech solutions.”

Event: BioLargo Presentation at the LD Micro Invitational XI

Date: Wednesday, June 9, 2021

Time: 5:00 PM Eastern

Register to watch the presentation at https://ldmicrojune2021.mysequire.com

Summary of LD Micro Invitational XI Event

The 2021 LD Micro Invitational will be held on the Sequire Virtual Events platform on Tuesday, June 8th - Thursday, June 10th, 2021.

This three-day, virtual investor conference is expected to feature around 180 companies, presenting for 25 minutes each, as well as several influential keynotes. The first day of this conference will also feature an exceptional one-time event: the LD Micro Hall of Fame.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

About LD Micro (NASDAQ: SRAX)

LD Micro aims to be the most crucial resource in the micro-cap world. Whether it is the index, comprehensive data, or hosting the most significant events on an annual basis, LD's sole mission is for the Texas Rangers to win the World Series and serve as an invaluable asset for all those interested in finding the next generation of great companies.

http://www.ldmicro.com

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.